Chimerism evaluation in measurable residual disease-suspected cells isolated by flow cell sorting as a reliable tool for measurable residual disease verification in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
chimerism
flow cell sorting
hematopoietic stem cell transplantation
measurable residual disease
Journal
Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
27
11
2020
received:
15
09
2020
accepted:
15
12
2020
pubmed:
29
12
2020
medline:
8
2
2022
entrez:
28
12
2020
Statut:
ppublish
Résumé
The presence of minimal/measurable residual disease (MRD) before or after hematopoietic stem cell transplantation (HSCT) is known as a predictor of poor outcome in patients with acute myeloid (AML) or lymphoblastic (ALL) leukemia. When performed with multiparameter flow cytometry (MFC), assessment of residual leukemic cells after HSCT may be limited by therapy-induced shifts in the immunophenotype (e.g., loss of surface molecules used for therapeutic targeting). However, in such cases, questionable cells can be isolated and tested for hematopoietic chimerism to clarify their origin. Questionable cell populations were detected during the MFC-based MRD monitoring of 52 follow-up bone marrow samples from 37 patients diagnosed with T cell neoplasms (n =14), B cell precursor ALL (n = 16), AML (n = 7). These cells (suspected leukemic or normal) were isolated by flow cell sorting and tested for hematopoietic chimerism by RTQ-PCR. The origin of cells was successfully identified in 96.15% of cases (n = 50), which helped to validate the results of MFC-based MRD monitoring. We believe that a combination of MFC, cell sorting, and chimerism testing may help confirm or disprove MRD presence in complicated cases after HSCT.
Sections du résumé
BACKGROUND
The presence of minimal/measurable residual disease (MRD) before or after hematopoietic stem cell transplantation (HSCT) is known as a predictor of poor outcome in patients with acute myeloid (AML) or lymphoblastic (ALL) leukemia. When performed with multiparameter flow cytometry (MFC), assessment of residual leukemic cells after HSCT may be limited by therapy-induced shifts in the immunophenotype (e.g., loss of surface molecules used for therapeutic targeting). However, in such cases, questionable cells can be isolated and tested for hematopoietic chimerism to clarify their origin.
METHODS
Questionable cell populations were detected during the MFC-based MRD monitoring of 52 follow-up bone marrow samples from 37 patients diagnosed with T cell neoplasms (n =14), B cell precursor ALL (n = 16), AML (n = 7). These cells (suspected leukemic or normal) were isolated by flow cell sorting and tested for hematopoietic chimerism by RTQ-PCR.
RESULTS
The origin of cells was successfully identified in 96.15% of cases (n = 50), which helped to validate the results of MFC-based MRD monitoring.
CONCLUSIONS
We believe that a combination of MFC, cell sorting, and chimerism testing may help confirm or disprove MRD presence in complicated cases after HSCT.
Identifiants
pubmed: 33369016
doi: 10.1002/cyto.b.21982
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
568-573Informations de copyright
© 2020 International Clinical Cytometry Society.
Références
Abou Dalle, I., Jabbour, E., & Short, N. J. (2020). Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 11, 2040620720910023.
Buldini, B., Maurer-Granofszky, M., Varotto, E., & Dworzak, M. N. (2019). Flow-cytometric monitoring of minimal residual disease in pediatric patients with acute myeloid leukemia: Recent advances and future strategies. Frontiers in Pediatrics, 7, 412.
Czyz, A., & Nagler, A. (2019). The role of measurable residual disease (MRD) in hematopoietic stem cell transplantation for hematological malignancies focusing on acute leukemia. International Journal of Molecular Sciences, 20(21), 53-62.
Gendzekhadze, K., Gaidulis, L., & Senitzer, D. (2013). Chimerism testing by quantitative PCR using Indel markers. Methods in Molecular Biology, 1034, 221-237.
Giebel, S., Czyz, A., Ottmann, O., Baron, F., Brissot, E., Ciceri, F., Cornelissen, J. J., Esteve, J., Gorin, N. C., Savani, B., Schmid, C., Mohty, M., & Nagler, A. (2016). Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 122(19), 2941-2951.
Illarionova, O., Glukhanyuk, E., Kashpor, S., Plyasunova, S., Maschan, A. A., Miakova, N., & Popov, A. (2017). Changes in leukemic blasts CD19 expression in children with relapsed/refractory B-cell precursor ALL treated with blinatumomab. Blood, 130(Supp. 1), 3991.
Jaso, J. M., Wang, S. A., Jorgensen, J. L., & Lin, P. (2014). Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: Past, present and future. Bone Marrow Transplantation, 49(9), 1129-1138.
Kiss, F., Buslig, J., Szegedi, I., Scholtz, B., Kappelmayer, J., & Kiss, C. (2008). Early relapse after rituximab chemoimmunotherapy. Pediatric Blood & Cancer, 50(2), 372-375.
Mejstríková, E., Hrusak, O., Borowitz, M. J., Whitlock, J. A., Brethon, B., Trippett, T. M., Zugmaier, G., Gore, L., von Stackelberg, A., & Locatelli, F. (2017). CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer Journal, 7(12), 659. https://doi.org/10.1038/s41408-017-0023-x.
Popov, A. M., Belevtsev, M. V., Boyakova, E. V., Verzhbitskaya, T. Y., Movchan, L. V., Fadeeva, M. S., Pashchenko, А. B., Savitskiy, V. P., Levadnyy, А. A., Tsaur, G. А., Kashpor, S. A., Plyasunova, S. A., Fechina, L. G., Aleynikova, O. V., & Karachunskiy, A. I. (2016). Standardization of flow cytometric minimal residual disease monitoring in children with B-cell precursor acute lymphoblastic leukemia. Russia-Belarus multicenter group experience. Oncohematology., 11(4), 64-73 In Russ.
Schuurhuis, G. J., Heuser, M., Freeman, S., Bené, M. C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., Jorgensen, J. L., Kern, W., Lacombe, F., Maurillo, L., Preudhomme, C., van der Reijden, B. A., Thiede, C., Venditti, A., Vyas, P., … Ossenkoppele, G. J. (2018). Minimal/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party. Blood, 131, 1275-1291.
Shah, M. V., Jorgensen, J. L., Saliba, R. M., Wang, S. A., Alousi, A. M., Andersson, B. S., Bashir, Q., Ciurea, S. O., Kebriaei, P., Marin, D., Patel, K. P., Popat, U. R., Rezvani, K., Rondon, G., Shpall, E. J., Champlin, R. E., & Oran, B. (2018). Early post-transplant minimal residual disease assessment improves risk stratification in acute myeloid leukemia. Biology of Blood and Marrow Transplantation, 24(7), 1514-1520.
van Dongen, J. J., van der Velden, V. H., Brüggemann, M., & Orfao, A. (2015). Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies. Blood, 125(26), 3996-4009.
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., & Li, Y. (2019). Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Frontiers in Immunology, 10, 2664.